| 84.86 Data as of Jun 19 |  -1.50 / -1.74%Today’s Change | 66.14 Today|||52-Week Range 89.99 | +21.06% Year-to-Date |
| Ibrutinib Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Data Published in... Jun 19 / Investing Channel | The FDA Might Pull This Drug From the Market (and Why It Doesn't Matter) Jun 18 / MotleyFool.com |
| Johnson & Johnson (JNJ): Today's Featured Drugs Laggard Jun 19 / TheStreet.com | Should You Buy Stocks Discarded By Warren Buffett ? Jun 18 / MotleyFool.com |
| Labor Market's Loss = Investors' Gain: Worth it? - Analyst Blog Jun 19 / Zacks.com | Old CEO, New Prospects Jun 18 / MotleyFool.com |
| Three Growing Companies Building Powerful Brands Jun 19 / MotleyFool.com | Johnson & Johnson Gets Key Cancer Drug With Aragon Buy Jun 18 / TheStreet.com |
| The Top 3 Medical Uses of Botox Jun 18 / MotleyFool.com | J&J to Buy Aragon for $1 Billion - Analyst Blog Jun 18 / Zacks.com |
| Previous close | 86.36 |
| Today’s open | 86.43 |
| Day’s range | 84.80 - 86.50 |
| Volume | 8,288,594 |
| Average volume (3 months) | 9,760,487 |
| Market cap | $242.6B |
| Dividend yield | 3.11% |
| Earnings growth (last year) | +10.60% |
| Earnings growth (this year) | +6.09% |
| Earnings growth (next 5 years) | +6.40% |
| Revenue growth (last year) | +3.45% |
| P/E ratio | 23.1 |
| Price/Sales | 2.84 |
| Price/Book | 3.70 |
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer Inc | -0.30 | -1.02% |
| NVSNovartis AG | -1.22 | -1.67% |
| SNYSanofi SA | -1.16 | -2.13% |
| MRKMerck & Co Inc | -0.17 | -0.36% |
| Next reporting date | July 16, 2013 |
| EPS forecast (this quarter) | $1.39 |
| Annual revenue (last year) | $67.3B |
| Annual profit (last year) | $10.9B |
| Net profit margin | 16.13% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman & Chief Executive Officer Alex Gorsky, MBA |
Chief Financial Officer & Vice President Dominic J. Caruso |
Corporate headquarters New Brunswick, New Jersey |
.
